Introduction
For many years the standard treatment of hypoparathyroidism has been vitamin D (calciferol) in large doses-generally 0-5-2 mg daily. This contrasts with the physiological requirement which, in adults, is of the order of 2-5 ,ug/day. In recent years it has been shown that hypoparathyroidism responds to microgram doses of the vitamin D metabolite 1,25-dihydroxycholecalciferol (1,25(OH)D3) or similar doses of loa-hydroxycholecalciferol (alphacalcidol) which is converted in the liver to 1,25(OH)2D3 (Russell et al., 1974; Kooh et al., 1974; Neer, Holick and Potts, 1975; Davies et al., 1977 (Kanis and Russell, 1977) . Three patients are now reported who became hypercalcaemic on alphacalcidol, and the causes of this are sought.
Patients
The 3 patients were all women and all had hypoparathyroidism after thyroid surgery. One (case one) had been previously treated with dihydrotachysterol but was transferred to alphacalcidol as she was persistently hypocalcaemic. The (Brickman et al., 1976) , and the full response to a given dose may not be seen for several weeks. As with calciferol the key to the prevention of hypercalcaemia is constant vigilance; as with calciferol a plasma calcium level rising rapidly within the normal range is a signal for stopping the drug (Paterson, 1980) . The speed of action of alphacalcidol is such not only that normocalcaemia may be achieved more rapidly than with calciferol-but hypercalcaemia may also supervene more rapidly. With calciferol it is usually suggested that patients should be seen not less often than once every 4 months even when the plasma calcium is apparently stable (Paterson, 1980; Davies and Adams, 1978) . A corresponding period for alphacalcidol is probably one month. The controlling step in normal vitamin D metabolism is the second hydroxylation (the loc-hydroxylation) which takes place in the kidney. By the use of alphacalcidol this key step is bypassed and accumulation of 1,25-dihydroxycholecalciferol is likely to occur. Although alphacalcidol has only been available for a short time, some of the practical difficulties have become clear. For example the administration of anticonvulsants diminishes the response to alphacalcidol (Lewin et al., 1978) . There is some evidence too, that alphacalcidol may impair renal function even in normal people (Compston, Horton and Laker, 1979) .
While alphacalcidol may be valuable for the early treatment of the hypoparathyroid patient with symptoms (Gertner, Hodsman and Neuberger, 1976) , it is likely that calciferol will remain the drug of choice in long-term maintenance. 
